Pre-analytical requirements and published findings by bile-derived biomarker class.
| Analyte class | Bile volume used (published studies) | Critical pre-analytical variables | Key published findings | Outstanding gaps |
|---|---|---|---|---|
| cfDNA/ctDNA | 1 mL (Arechederra et al. [9]); 3–6 mL (Li et al. [13]); ≥ 10 mL (Han et al. [14]) | Early cell/debris removal; centrifugation protocol; tube type; storage temperature and duration; extraction method (bile-specific vs. plasma kits) | Preservation tubes maintain stability ≤ 10 days at RT and ≤ 2 months at 4°C [18]; 3D-BCF method recovers full fragment-size distribution [17]; stability up to 7 h at RT shown for ctDNA [14] | No standardised minimum volume; optimal centrifugation parameters not established across laboratories; cfDNA yield vs. volume relationship not quantified in bile |
| DNA methylation | Not consistently reported | Similar to cfDNA; input DNA quality critical for ddPCR assays | ddPCR methylation assays (CDO1, CNRIP1, SEPT9, VIM) validated in bile from PSC cohorts [19, 20] | Methylation-specific extraction requirements in bile not validated; freeze-thaw effects unstudied |
| microRNA/non-coding RNA | Not consistently reported | EV isolation method (ultracentrifugation vs. precipitation vs. SEC); RNA extraction kit; freeze-thaw cycles; time to freezing | EV-protected RNA more stable than free RNA in bile [15, 22, 23]; bile miRNA profiles distinguish BTC from benign disease [23] | No bile-specific RNA extraction validation; EV isolation inconsistently reported; miRNA stability in bile not formally assessed |
| EVs | Not consistently reported | Isolation method (ultracentrifugation, SEC, precipitation); bile viscosity and bile salt interference; storage temperature; MISEV2023 reporting standards [39] | EV cargo can distinguish malignant from benign biliary disease [22, 23, 25, 27]; phosphatidylcholine identified in CCA-derived EVs [27] | Heterogeneous isolation methods; inconsistent nomenclature; no bile-specific EV characterisation standards; all studies small (n = 7 malignant, n = 15 total in Muraki et al. [27]) |
| Proteomics/lipidomics/metabolomics | 40–50 mL (bile proteomics [29]); not stated for most lipidomic studies | Immediate freezing; bacterial contamination; bile dilution; freeze-thaw cycles; instrument batch effects | BileLipid classifier (6-lipid panel, AUC 0.828–0.956 across cohorts) [30]; bile microbiome + metabolite signatures distinguish CCA from PSC [32]; POSTN identified via bile proteomics [29] | Complex analytical pipelines; susceptible to ERCP duodenal flora contamination [32]; external validation lacking; no consensus on sample preparation |
cfDNA: cell-free DNA; ddPCR: droplet digital polymerase chain reaction; ERCP: endoscopic retrograde cholangiopancreatography; EV: extracellular vesicle; MISEV2023: Minimal Information for Studies of Extracellular Vesicles 2023; PSC: primary sclerosing cholangitis; RT: room temperature; SEC: size-exclusion chromatography; BTC: biliary tract cancer.